Next Article in Journal
COVID-19 Vaccination in Pregnancy: Pilot Study for Maternal and Neonatal MicroRNA Profiles
Next Article in Special Issue
RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques
Previous Article in Journal
Global Analysis of Tracking the Evolution of SARS-CoV-2 Variants
Previous Article in Special Issue
A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 12
10.3390/vaccines11121813
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases

by
José M. Serra López-Matencio
1,*,
Esther F. Vicente-Rabaneda
2,
Estefanía Alañón
1,
Ainhoa Aranguren Oyarzabal
1,
Pedro Martínez Fleta
3 and
Santos Castañeda
2,*
1
Hospital Pharmacy Service, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain
2
Rheumatology Service, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain
3
Immunology Service, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Vaccines 2023, 11(12), 1813; https://doi.org/10.3390/vaccines11121813
Submission received: 16 October 2023 / Revised: 25 November 2023 / Accepted: 30 November 2023 / Published: 4 December 2023
(This article belongs to the Special Issue COVID Vaccines: Design, Development, and Immune Response Studies)
Browse Figure
Review Reports Versions Notes

Abstract

The COVID-19 vaccination program has probably been the most complex and extensive project in history until now, which has been a challenge for all the people involved in the planning and management of this program. Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have required special attention, not only because of the particular haste in carrying out the process but also because of the uncertainty regarding their response to the vaccines. We now have strong scientific evidence that supports the hypothesis that immunosuppressive therapy inhibits the humoral response to vaccines against other infectious agents, such as influenza, pneumococcus and hepatitis B. This has led to the hypothesis that the same could happen with the COVID-19 vaccine. Several studies have therefore already been carried out in this area, suggesting that temporarily discontinuing the administration of methotrexate for 2 weeks post-vaccination could improve the vaccine response, and other studies with various immunosuppressive drugs are in the same line. However, the fact of withholding or interrupting immunosuppressive therapy when dealing with COVID-19 vaccination remains unclear. On this basis, our article tries to compile the information available on the effect of immunosuppressant agents on COVID-19 vaccine responses in patients with IMIDs and proposes an algorithm for the management of these patients.
Keywords: COVID-19; vaccination; immunosuppressive therapy; immune-mediated inflammatory diseases (IMIDs); DMARDs; biological drugs; targeted synthetic DMARDs COVID-19; vaccination; immunosuppressive therapy; immune-mediated inflammatory diseases (IMIDs); DMARDs; biological drugs; targeted synthetic DMARDs

Share and Cite

MDPI and ACS Style

Serra López-Matencio, J.M.; Vicente-Rabaneda, E.F.; Alañón, E.; Aranguren Oyarzabal, A.; Martínez Fleta, P.; Castañeda, S. COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases. Vaccines 2023, 11, 1813. https://doi.org/10.3390/vaccines11121813

AMA Style

Serra López-Matencio JM, Vicente-Rabaneda EF, Alañón E, Aranguren Oyarzabal A, Martínez Fleta P, Castañeda S. COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases. Vaccines. 2023; 11(12):1813. https://doi.org/10.3390/vaccines11121813

Chicago/Turabian Style

Serra López-Matencio, José M., Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, and Santos Castañeda. 2023. "COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases" Vaccines 11, no. 12: 1813. https://doi.org/10.3390/vaccines11121813

APA Style

Serra López-Matencio, J. M., Vicente-Rabaneda, E. F., Alañón, E., Aranguren Oyarzabal, A., Martínez Fleta, P., & Castañeda, S. (2023). COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases. Vaccines, 11(12), 1813. https://doi.org/10.3390/vaccines11121813

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop